Michael Hayes’s take
The decision behind the offer.
Ivy’s $77 headline gets attention, but it does not do enough to identify the offer. I would compare only after the medication, four-dose supply and renewal amount are written together.
See the cost and care breakdownIn this review
What you are paying for
Looking beyond a low starting price
- Care
- Physician review and live support advertised
- Medication
- Compounded injection; separate branded and microdose listings
- Commitment
- Confirm what the four-dose starting price includes and what renews
What stands out
- Dose-independent pricing advertised
- Physician review and delivery described
Where I would pause
- Headline is not a complete individual quote
- Microdose and full-dose listings need separation
Four doses is the unit worth noticing
Ivy’s injection page displays a starting price of $77 for four doses per month. It describes compounded semaglutide and tirzepatide, but that headline alone does not identify the particular ingredient, formulation or commitment behind the lowest price.
My comparison would start with the prescription and the supplied quantity. If billing follows four weeks rather than calendar months, that distinction changes an annual budget; ask for the actual billing interval instead of assuming it from the word month.
Do not let the wider storefront blur the choice
Ivy also lists branded products, microdose offerings and other wellness products. Those are separate decisions. An inexpensive microdose listing should not be substituted into a price comparison for a different prescribed plan.
For the injection program, Ivy advertises clinician review, delivery and a stable price as a prescribed dose changes. Those are provider descriptions. We have not tested the speed of its review or customer support, and the presence of a message channel does not establish how quickly a clinical concern is answered.
Does this care model fit?
Review the current offer and the terms for your selected plan.
The labwork message is not individual medical advice
The product page says labwork is not needed. I would treat that as a description of the advertised enrollment pathway, not a reason to decline testing a clinician recommends for an individual patient. The service should explain how it evaluates medical history and handles questions that require more than an online form.
Ivy’s compounded products are not FDA-approved. Ask for the dispensing pharmacy and exact preparation, especially when moving from a branded product. The switching checklist helps keep the record-transfer and follow-up questions together.
Where Ivy fits in a shortlist
Compare Ivy with Yucca for another included-care offer and with Trimi for a more explicit monthly-versus-prepaid bill. This is a comparison of commercial terms, not a finding that their medications are interchangeable.
Ivy is worth requesting a quote from if you are evaluating self-pay compounded care. I would not label it the cheapest option from the starting price: the unresolved plan details are precisely the details a fair price comparison needs.
A different fit might be better.
Compare the reason for choosing each service, not just the name on the offer.
Yucca Health
Compare another bundle without assuming the starting prices describe identical plans.
Compare side by sideTrimi
Use an explicit payment schedule as a reference for your quote.
Compare side by sideBased on published provider information, not personal treatment. Our review standards explain how we assess offers. A clinician must determine individual treatment suitability.